The content on this site is intended for healthcare professionals only
Dr Pandha speaks with ecancertv at ESMO 2016 about two trials of coxsackie virus as an immune modulator.
Oncolytic virotherapy is discussed more broadly in an ecancer review here.
Dr Pandha describes results from the CANON trial of virotherapy for bladder cancer, and the STORM / KEYNOTE200 trial which combined virotherapy with immune modulator pembrolizumab.
He describes how viral stimulation of immune activity, further enhanced by checkpoint inhibitors, can have significant outcomes, and considers wider adoption of virotherapy to complement other treatment modalities.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
GIST tumours and soft tissue sarcomas
Multiple myeloma in a resource constrained setting
The current status of multiple myeloma diagnosis and treatment
Choosing Wisely in radiology Tanzania
